Rilpivirine
| Clinical data | |
|---|---|
| Trade names | Edurant, Rekambys, others | 
| Other names | TMC278 | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a611037 | 
| License data | 
 | 
| Pregnancy category | 
 | 
| Routes of administration | By mouth, intramuscular | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 99.7% | 
| Metabolism | CYP3A4 | 
| Elimination half-life | tablets: 45 hours injection: 13–28 weeks | 
| Excretion | 85% via faeces, 6% via urine | 
| Identifiers | |
| 
 | |
| CAS Number | 
 | 
| PubChem CID | |
| DrugBank | 
 | 
| ChemSpider | |
| UNII | 
 | 
| KEGG | |
| ChEBI | 
 | 
| ChEMBL | 
 | 
| NIAID ChemDB | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.224.394 | 
| Chemical and physical data | |
| Formula | C22H18N6 | 
| Molar mass | 366.428 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Rilpivirine, sold under the brand name Edurant among others, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.